HITECH

Chennai, India Founded: 1986 • Age: 40 yrs Listed Acquired By Metropolis India
Chain of diversified clinical laboratory centers
Request Access
Report Incorrect Data
Page last updated

About HITECH

HITECH is a publicly listed company based in Chennai (India) founded in 1986, and was acquired by Metropolis India in October 2021. Chain of diversified clinical laboratory centers. The company has 698 employees. Its Indian entity Metropolis Healthcare Limited reported revenue of ₹1,671 Cr. Its focus areas include Clinical Laboratory Chains and Diversified. Its competitors include Thyrocare, Vijaya Diagnostic Centre and Suraksha Diagnostics; 2 of its 3 listed competitors have raised funding.

Company details

HITECH was established in 1986 in Chennai, India, within the healthcare sector. A network of clinical laboratory centers is maintained to deliver diagnostic services. Testing for medical conditions is conducted across multiple facilities, supporting diversified laboratory operations. The focus remains on routine and specialized diagnostics, with primary activities centered in India. Expansion has been pursued through additional centers to enhance service reach.

Operational Areas
Healthcare → Diagnostics Laboratories
Key Metrics
  • Market Cap
    ₹12,063 Cr

    METROPOLIS · NSE

  • Share Price
    ₹571.00

    -1.76% today

  • Revenue
    ₹1,646 Cr

    FY 2025-26 · +23.6% YoY

  • EBITDA
    ₹396 Cr

    Margin 24.1%

  • Net Profit
    ₹194 Cr

    FY 2025-26 · +42.3% YoY

  • P/E (TTM)
    55.8x

    P/B 7.7x

  • ROE
    13.4%

    ROCE 17.2%

  • Debt / Equity
    0.15

    Interest cover 11.0x

  • Investors
    Metropolis India
  • Employee Count
    698
  • Acquired by
    Metropolis India

    (Oct 2021)

Investors in HITECH

HITECH has secured backing from 1 investor. Prominent investors backing the company include Metropolis India.

All
InvestorDescriptionFounded YearDomainLocation
Metropolis India
Diagnostic centers are operated as a nationwide chain.
1981metropolisindia.comMumbai, India
Premium access

Investor details for HITECH

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Metropolis Healthcare Limited (HITECH)

Metropolis Healthcare Limited is the primary company behind HITECH. The boards of the 2 registered companies of HITECH currently have 13 directors; the longest-serving is Sushil Kanubhai Shah, appointed in 2005. 35 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Sushil Kanubhai Shah
DIN 00179918
Director17 Aug 200521 yrs 2 moMetropolis Healthcare Limited
Ameera Sushil Shah
DIN 00208095
Whole-time director06 May 200818 yrs 5 moMetropolis Healthcare Limited, Dr.Ganesan's Hitech Diagnostic Centre Private Limited
Subramanian Ganesan
DIN 02013825
Managing Director18 Feb 200917 yrs 8 moDr.Ganesan's Hitech Diagnostic Centre Private Limited
Vivek Gambhir
DIN 06527810
Director07 Sep 20188 yrs 1 moMetropolis Healthcare Limited
Sanjay Bhatnagar
DIN 00867848
Director07 Sep 20188 yrs 1 moMetropolis Healthcare Limited
Hemant Sachdev
DIN 01635195
Director27 May 20215 yrs 5 moMetropolis Healthcare Limited
Rakesh Kumar Agarwal
DIN 08614903
Director22 Oct 20215 yrsDr.Ganesan's Hitech Diagnostic Centre Private Limited
Alangadan Kannan
DIN 09151786
Director22 Oct 20215 yrsDr.Ganesan's Hitech Diagnostic Centre Private Limited
Subramanian Ranganathan
DIN 00125493
Director21 Aug 20233 yrs 2 moMetropolis Healthcare Limited
Aparna Chetan Rajadhyaksha
DIN 10596037
Director22 May 20242 yrs 5 moMetropolis Healthcare Limited
Purvi Sheth
DIN 06449636
Director17 Mar 20251 yr 7 moMetropolis Healthcare Limited
Rehan Khan Abbas
DIN 02616924
Director13 May 20251 yr 5 moMetropolis Healthcare Limited
Chemmenkotil Surendran
DIN 10818890
Managing Director01 Jun 20251 yr 5 moMetropolis Healthcare Limited

IPO & Listings of HITECH

HITECH is a publicly listed company on the NSE with ticker symbol METROPOLIS in India, operating in the Healthcare sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • Listed onNSE: METROPOLIS
  • Listed entityMetropolis Healthcare Limited
  • Exchange sectorHealthcare

Financials of HITECH

Exchange-reported figures of Metropolis Healthcare Limited, the listed company behind HITECH (NSE: METROPOLIS).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹1,646 Cr
+23.6% YoY
EBITDA
₹396 Cr
+28.5% YoY
Profit After Tax
₹194 Cr
+42.3% YoY
Net Worth
₹1,513 Cr
+13.7% YoY
Total Assets
₹1,792 Cr
+14.5% YoY
Total Debt
₹232 Cr
+13.6% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,6461,3311,2081,1481,228998856
Revenue growth+23.6%+10.2%+5.2%-6.5%+23.1%+16.5%-
EBITDA396308288293348290212
EBITDA margin+24.1%+23.2%+23.8%+25.6%+28.3%+29.0%+24.8%
Profit before tax259191175188293244169
Net profit194136127143203183144
Net profit margin+11.8%+10.2%+10.5%+12.4%+16.5%+18.3%+16.8%
EPS (₹)9.1727.9924.9527.9041.8635.8225.15
Balance sheet
Total assets1,7921,5661,3121,2711,279830602
Net worth1,5131,3311,096988886707524
Total debt23220419726637911266.70
Cash & bank62.3249.0271.2293.19167420210
Net working capital87.5974.4394.88137215430236
Cash flow
Cash from operations351263264247253249215
Cash from investing(220)(199)(89.09)48.09(736)63.08(104)
Cash from financing(115)(86.63)(181)(292)163(32.69)(55.32)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue450425406429386345323350
Revenue growth (YoY)+16.6%+23.0%+25.8%+22.7%+23.2%---
Other income5.108.279.020.897.526.972.563.13
EBITDA11110885.7510889.7562.2972.0189.88
EBITDA margin+24.7%+25.4%+21.1%+25.2%+23.2%+18.0%+22.3%+25.7%
Depreciation32.4038.5931.8832.4130.8528.6227.7026.82
Interest6.187.935.735.685.204.604.534.79
Profit before tax77.7269.7757.1671.0261.2236.0442.3461.40
Tax20.8318.8015.0718.1315.986.8210.8614.70
Net profit56.8950.9742.0952.8945.2429.2231.4846.70
EPS (₹)2.732.467.9410.138.665.666.099.03
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,3651,2161,1031,0661,157816665
Revenue growth+12.3%+10.2%+3.5%-7.9%+41.8%+22.7%-
EBITDA334272263274324242152
EBITDA margin+24.5%+22.4%+23.9%+25.7%+28.0%+29.7%+22.8%
Profit before tax212162157179272246140
Net profit161116115139188198130
Net profit margin+11.8%+9.6%+10.4%+13.0%+16.2%+24.2%+19.5%
EPS (₹)7.6024.0922.6227.1338.9938.6522.13
Balance sheet
Total assets1,6021,4461,2421,2171,229801572
Net worth1,3891,2441,031936839709512
Total debt18217819526837784.9753.54
Cash & bank20.5525.5230.4642.94115335132
Net working capital9.7122.1661.97112189384185
Cash flow
Cash from operations318273269238244202156
Cash from investing(209)(194)(81.51)46.72(736)73.53(51.13)
Cash from financing(111)(84.50)(183)(288)172(26.33)(46.37)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue372352335356324312297322
Revenue growth (YoY)+15.0%+12.9%+12.7%+10.6%+13.1%---
Other income5.198.822.222.522.787.763.033.59
Total expenses279262263264247259232240
EBITDA93.6990.1372.1991.3577.0552.5265.1082.02
EBITDA margin+25.2%+25.6%+21.6%+25.7%+23.8%+16.9%+21.9%+25.5%
Depreciation27.8132.8027.7227.7927.8627.2726.8526.01
Interest4.776.564.373.974.294.434.494.73
Profit before tax66.3059.5942.3262.1147.6828.5836.7954.87
Tax15.7216.3510.2915.4812.104.739.3912.61

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 05 Nov 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue450425406429386345323350
Revenue growth (YoY)+16.6%+23.0%+25.8%+22.7%+23.2%---
Other income5.108.279.020.897.526.972.563.13
EBITDA11110885.7510889.7562.2972.0189.88
EBITDA margin+24.7%+25.4%+21.1%+25.2%+23.2%+18.0%+22.3%+25.7%
Depreciation32.4038.5931.8832.4130.8528.6227.7026.82
Interest6.187.935.735.685.204.604.534.79
Profit before tax77.7269.7757.1671.0261.2236.0442.3461.40
Tax20.8318.8015.0718.1315.986.8210.8614.70
Net profit56.8950.9742.0952.8945.2429.2231.4846.70
EPS (₹)2.732.467.9410.138.665.666.099.03
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,6461,3311,2081,1481,228998856
Revenue growth+23.6%+10.2%+5.2%-6.5%+23.1%+16.5%-
Other income25.5815.119.1215.2233.6212.058.57
Total expenses1,2501,023920855880708644
Employee cost377314276253233199190
EBITDA396308288293348290212
EBITDA margin+24.1%+23.2%+23.8%+25.6%+28.3%+29.0%+24.8%
Depreciation13410994.4789.2263.2245.9439.27
Interest28.9023.8927.8931.8525.0211.5612.65
Profit before tax259191175188293244169
Tax67.9945.3446.2344.1178.6660.9741.18
Net profit194136127143203183144
Net profit margin+11.8%+10.2%+10.5%+12.4%+16.5%+18.3%+16.8%
EPS (₹)9.1727.9924.9527.9041.8635.8225.15
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital41.4710.3610.2510.2410.2310.2210.13
Reserves & surplus1,4611,3131,078978876696513
Shareholders' funds (net worth)1,5131,3311,096988886707524
Minority interest11.393.673.122.481.971.461.66
Secured loans18.7314.190.0079.052590.000.00
Unsecured loans21319019718712011266.70
Total debt23220419726637911266.70
Total liabilities1,7921,5661,3121,2711,279830602
Assets
Gross block1,9011,6971,3821,2961,192438366
Net block1,6011,4471,1771,1211,059343296
Capital work in progress0.000.000.0019.515.780.002.99
Investments14271.0054.8314.8115.5110.0814.32
Inventories45.4947.8438.6944.5951.1140.5524.40
Sundry debtors170148126122135123128
Cash & bank balances62.3249.0271.2293.19167420210
Loans & advances49.8731.8926.5730.0025.8416.9121.37
Total current assets328277263290379600384
Total current liabilities240202168153164171149
Net working capital87.5974.4394.88137215430236
Total assets1,7921,5661,3121,2711,279830602
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash39.4862.6268.8365.9838710751.37
Net cash from operating activities351263264247253249215
Net cash from investing activities(220)(199)(89.09)48.09(736)63.08(104)
Net cash from financing activities(115)(86.63)(181)(292)163(32.69)(55.32)
Net change in cash15.31(23.14)(6.21)2.85(321)27955.80
Closing cash62.3249.0271.2293.19167420210
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+23.6%+10.2%+5.2%-6.5%+23.1%+16.5%-
EBITDA growth+28.5%+7.1%-1.9%-15.7%+20.1%+36.6%-
PBT growth+35.8%+9.3%-6.8%-36.1%+20.1%+44.8%-9.6%
Net income growth+42.3%+7.2%-11.0%-29.5%+10.9%+27.0%-
Revenue CAGR (3Y)+12.8%+2.7%+6.6%+10.3%+17.3%+15.5%+16.3%
EBITDA CAGR (3Y)+10.5%-4.0%-0.2%+11.4%+19.8%+17.5%+11.4%
Profitability & leverage
Net income margin+11.6%+10.9%+10.6%+12.5%+17.5%+18.4%+14.9%
Return on capital employed+17.2%+15.0%+15.7%+17.2%+30.2%+35.8%+39.5%
Return on net worth+13.4%+12.0%+12.3%+15.3%+27.0%+29.8%+30.6%
Debt / equity0.150.170.220.340.310.150.09
Long-term debt / equity0.090.100.130.210.200.110.05
Interest cover11.0111.9714.4215.608.794.747.32
Efficiency & per share
Fixed asset turnover0.910.860.900.921.512.482.69
Inventory turnover35.2730.7729.0024.0026.8030.7333.92
Debtors turnover10.349.719.738.929.507.946.46
EPS (₹)9.1727.9924.9527.9041.8635.8225.15
Dividend per share (₹)5.000.004.008.008.008.008.00
Book value per share (₹)72.46255.41212.47192.97173.18138.23103.40
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue372352335356324312297322
Revenue growth (YoY)+15.0%+12.9%+12.7%+10.6%+13.1%---
Other income5.198.822.222.522.787.763.033.59
Total expenses279262263264247259232240
EBITDA93.6990.1372.1991.3577.0552.5265.1082.02
EBITDA margin+25.2%+25.6%+21.6%+25.7%+23.8%+16.9%+21.9%+25.5%
Depreciation27.8132.8027.7227.7927.8627.2726.8526.01
Interest4.776.564.373.974.294.434.494.73
Profit before tax66.3059.5942.3262.1147.6828.5836.7954.87
Tax15.7216.3510.2915.4812.104.739.3912.61
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,3651,2161,1031,0661,157816665
Revenue growth+12.3%+10.2%+3.5%-7.9%+41.8%+22.7%-
Other income16.6717.5012.0021.2832.1548.6529.32
Total expenses1,032944840792833574514
Employee cost297272247228218157148
EBITDA334272263274324242152
EBITDA margin+24.5%+22.4%+23.9%+25.7%+28.0%+29.7%+22.8%
Depreciation11610590.7384.9660.2636.2030.85
Interest22.8022.9927.2531.2924.548.7510.01
Profit before tax212162157179272246140
Tax54.1137.0741.5240.0072.0148.4927.93
Net profit161116115139188198130
Net profit margin+11.8%+9.6%+10.4%+13.0%+16.2%+24.2%+19.5%
EPS (₹)7.6024.0922.6227.1338.9938.6522.13
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital41.4710.3610.2510.2410.2310.2210.13
Reserves & surplus1,3371,2261,013926829699502
Shareholders' funds (net worth)1,3891,2441,031936839709512
Secured loans0.000.000.0079.052590.000.00
Unsecured loans18217819518911984.9753.54
Total debt18217819526837784.9753.54
Total liabilities1,6021,4461,2421,2171,229801572
Assets
Gross block1,3921,3461,3131,2291,131321265
Net block1,1351,1291,1201,0661,005251216
Capital work in progress0.000.000.0019.515.780.002.99
Investments48432189.7349.7150.41131130
Inventories32.2131.5533.8941.2747.0133.4617.46
Sundry debtors119114130126140123124
Cash & bank balances20.5525.5230.4642.94115335132
Loans & advances39.8119.7824.9841.9636.5924.8128.21
Total current assets211191219252339516302
Total current liabilities202168157140150132117
Net working capital9.7122.1661.97112189384185
Total assets1,6021,4461,2421,2171,229801572
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash22.6828.5924.0927.4934867.438.80
Net cash from operating activities318273269238244202156
Net cash from investing activities(209)(194)(81.51)46.72(736)73.53(51.13)
Net cash from financing activities(111)(84.50)(183)(288)172(26.33)(46.37)
Net change in cash(2.62)(5.90)4.50(3.40)(320)25058.63
Closing cash20.5525.5230.4642.94115335132
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+12.3%+10.2%+3.5%-7.9%+41.8%+22.7%-
EBITDA growth+22.6%+3.4%-3.8%-15.5%+33.8%+60.0%-
PBT growth+30.7%+2.8%-12.0%-34.1%+10.4%+75.8%-6.2%
Net income growth+38.3%+0.9%-17.1%-26.1%-4.9%+52.3%-
Revenue CAGR (3Y)+8.6%+1.7%+10.6%+17.0%+25.8%+19.0%+18.0%
EBITDA CAGR (3Y)+6.8%-5.7%+2.8%+21.8%+30.0%+21.1%+7.8%
Profitability & leverage
Net income margin+11.5%+10.3%+10.5%+13.0%+17.3%+24.2%+16.8%
Return on capital employed+15.4%+13.8%+15.0%+17.2%+29.2%+37.1%+34.6%
Return on net worth+12.0%+11.0%+11.8%+15.7%+25.8%+32.4%+28.0%
Debt / equity0.140.160.240.360.300.110.08
Long-term debt / equity0.080.100.140.220.190.080.04
Interest cover10.4713.7415.7816.569.304.248.30
Efficiency & per share
Fixed asset turnover1.000.910.870.901.592.782.83
Inventory turnover42.8337.1629.3624.1528.7632.0535.86
Debtors turnover11.749.988.618.008.796.615.48
EPS (₹)7.6024.0922.6227.1338.9938.6522.13
Dividend per share (₹)5.000.004.008.008.008.008.00
Book value per share (₹)66.47238.71199.79182.78164.00138.69101.20

Timeline of HITECH

2 dated milestones of HITECH across 35 years, from founding to its latest funding, stage changes and deals.

  1. Founded HITECH is founded.
  2. Exit Acquired by Metropolis India.

Competitors of HITECH

HITECH has 3 listed competitors in our database, 2 of them funded. They include Thyrocare, Vijaya Diagnostic Centre and Suraksha Diagnostics.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
Thyrocare
thyrocare.com1996Mumbai, India$63.59M1,889
Diagnostic testing centers for pathology and health screenings are operated.
Vijaya Diagnostic Centre
vijayadiagnostic.com1981Hyderabad, India
Diagnostic services are offered via a chain of centers.
Suraksha Diagnostics
surakshanet.com2005Kolkata, India$49M1,180
Pathology, molecular diagnostics, and imaging services are provided.
Premium access

Detailed competitors of HITECH

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of HITECH

The website of HITECH (hitechlabsindia.in) receives about 6.1K visits a month.

  • Monthly visits
    6.1K

    ▼ 65.6% vs previous month

Similar websites

Websites whose visitors overlap most with HITECH. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
BloodOxy
bloodoxy.com
100%
#4,458,008View details

Top companies in Diagnostics Laboratories

3 companies that operate in the same segment as HITECH (Diagnostics Laboratories) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Thyrocare
Diagnostic testing centers for pathology and health screenings are operated.
1996Mumbai, Maharashtra, IndiaUSD 63.59 MUSD 90.17 M1,979
Dr Lal PathLabs
Chain of pathology and radiology labs
1949Gurugram, Haryana, IndiaUSD 13.9 MUSD 294.49 M5,310
Redcliffe Labs
Home-based diagnostic tests are booked via an online platform.
2018Noida, Uttar Pradesh, IndiaUSD 116.42 MUSD 41.86 M2,308
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Hitech

Metropolis: Co Raises Lab Enhancement Outlook, Expecting 46% Boost in Lab Use by FY29 and Plan Price Increases in Q4 FY27 to Drive Higher Revenue and Margin Growth.
Exchange Update • 1 day ago
Metropolis: Co Guides For 120-170 Bps EBITDA Margin Expansion In Fy27, Backed By Planned Q4 B2C Price Hike And Lab Platform Completion
Exchange Update • 1 day ago
METROPOLIS: Q2 REVENUE 4.97B RUPEES VS 4.3B (YOY)
Exchange Update • 2 days ago
METROPOLIS: Q2 CONS NET PROFIT 753M RUPEES VS 527M (YOY)
Exchange Update • 2 days ago
METROPOLIS: Q2 EBITDA 1.34B RUPEES VS 1.1B (YOY); Q2 EBITDA MARGIN 26.96% VS 25.22% (YOY)
Exchange Update • 2 days ago
Metropolis Healthcare: Q2 FY27 Revenue Rises 15% Year-Over-Year Due To Strong Patient And Test Volume Growth, EBITDA Margins Increase.
Exchange Update • 1 month ago
Crisil Revises Metropolis Healthcare Outlook To 'Positive'; Reaffirms 'AA-' Rating – Outlook Business
Outlook Business • 1 month ago
Buy Metropolis Healthcare; target of Rs 675: ICICI Securities
Moneycontrol • 2 months ago
Buy Metropolis Healthcare; target of Rs 675: Emkay Global Financial
Moneycontrol • 2 months ago
METROPOLIS: Strong growth and margin expansion driven by specialty testing, technology, and network scale
Quartr • 2 months ago
Premium access

Complete news archive for HITECH

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about HITECH

HITECH was founded in 1986.

HITECH is headquartered in Chennai, India. It is registered at Chennai, Tamil Nadu, India.

HITECH has 698 employees.

The primary company behind HITECH, Metropolis Healthcare Limited, reported revenue of ₹1,671 Cr for FY 2026, up 24% year on year.

HITECH was established in 1986 in Chennai, India, within the healthcare sector. A network of clinical laboratory centers is maintained to deliver diagnostic services. Testing for medical conditions is conducted across multiple facilities, supporting diversified laboratory operations. The focus remains on routine and specialized diagnostics, with primary activities centered in India. Expansion has been pursued through additional centers to enhance service reach.

HITECH's top competitors include Thyrocare, Suraksha Diagnostics and Vijaya Diagnostic Centre.

Yes, HITECH is publicly traded on NSE under the ticker symbol METROPOLIS.

HITECH has 1 investor. Key investors include Metropolis India.

HITECH is associated with 2 legal entities: Metropolis Healthcare Limited, Dr.Ganesan's Hitech Diagnostic Centre Private Limited.

Yes. HITECH was acquired by Metropolis India in October 2021.

The legal entities of HITECH currently have 15 directors, including Ameera Sushil Shah, Sushil Kanubhai Shah, Hemant Sachdev and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available